The Solid Tumor Market in the Middle East and Africa is projected to rise at a steady CAGR during the forecast period.
There are fewer side effects, good therapy efficiency, and acceptable reimbursement schemes that are majorly driving the solid tumor market in this region. Around 8.2 million people died due to various cancers, as per the World Health Organization (WHO). This increasing incidence of cancer in the Middle East and Africa regions is a positive sign of the growth rate of the market. Drug approvals given by the U.S. FDA and favorable reimbursement policies for the solid tumor are further estimated to support the market growth in this region.
The costs associated with the treatments are so expensive, which is the primary inhibitor to market growth. Moreover, the costs associated with the R & D and strict administrative changes may impede the solid tumor market in Middle East & African during the forecast period.
This research report on the Middle East and Africa Solid Tumor Market has been segmented and sub-segmented into the following categories:
By Disease:
By Drugs:
By Country:
Regional Analysis:
The MEA solid tumor was accounted for the least share in the global market in 2019 among all the regions but expected to rise at a steady rate during the forecast period. UAE is expected to dominate the MEA solid tumor market with the highest share between 2020 to 2025. It is likely to develop different measures to bring out cancer awareness among the public and the treatment. The rising advent of medical tourism and the rise in medical expenditure present growth opportunities for the market. Also, the market key players' considerable investments in research and development for manufacturing drugs and advanced technologies in treatments like Herceptin are likely to flourish the market growth in the region. Moreover, other region countries are accounted to have a substantial increase in the region in the upcoming years throughout the period.
Notable companies leading the MEA Solid Tumor Market profiled in this report are Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi among others.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region